NBS. NeoStem Subsidiary, Amorcyte, Announces Significant Expansion in Its Claims Granted to Protect the Use of CD34+ Cells http://finance.yahoo.com/news/neostem-subsidiary-amorcyte-announces-significant-113000457.html stockcharts.com/c-sc/sc?s=NBS&p=W&yr=0&mn=9&dy=0&i=t13257083800&r=1347277399335